Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3419533 | Revue de Pneumologie Clinique | 2011 | 9 Pages |
Abstract
Bronchiolitis obliterans (BO) is a severe complication of hematopoietic stem cell transplantation (HSCT). It is considered as a respiratory manifestation of chronic graft-versus-host disease. It is quite similar to the bronchiolitis obliterans after lung transplantation. Classical therapy associates steroids and immunosuppressive drugs, however theses procedure showed a modest efficacy and have an important morbidity. Recent progresses in the physiopathology of BO post-HSCT allow to use new treatments: mTOR inhibitors, immunotherapy, extra-corporeal photochemotherapy, and bronchial anti-inflammatory effects of azithromycin, statins or antileucotriens. This review will focus on the use of these new therapies in BO post-HSCT.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
F. Lemonnier, N. Dhedin, Ã. Catherinot, C. Tcherakian, H. Neveu, F. Suarez, M.-H. Becquemin, P. Devillier, J.-P. Vernant, L.-J. Couderc, Ã. Rivaud,